Newsletter subscription & archive
Biopeople

Keep an eye on our Network Member, the Danish biotech company Cobo Technologies - potential to influence future drug development

06-05-2019

Congratulations to our Network Member Jens-Ole Bock, CEO at Cobo Technologies, who has been appointed to a consortium under the US National Institute of Standards and Technology (NIST) that is to advise the health authorities on clinical trials with the promising genome editing tool, CRISPR. The company's proprietary product can potentially become the standard quality control of CRISPR-based treatments

Cobo Technologies is specialised in gene editing products and services and focus on CRISPR Tools, such as the PIPPR, Protein Expression analysis Platform, which is the company's trademark.They are now entering the US market under The NIST Genome Editing Consortium. The NIST Genome Editing Consortium consists of 29 companies and research institutes. The company's proprietary product can potentially become the standard quality control of CRISPR-based treatments.

Learn more about Cobo Technologies and their PIPPR trademark

Close
What are you looking for?
By using this website, you agree to the use of cookies to give you the best user experience.
Find additional information at Cookies
Ok